Randomized Trials | Page 14 of 58 | Links Medicus Content Curation & Alerts in Medicine

RCT | Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma

12 May, 2023 | 13:18h | UTC

Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial – Cell Reports Medicine

News Release: ChemoID platform-predicted treatments lead to longer survival for glioblastoma patients – University of Cincinnati

Commentary on Twitter

Online now: Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial https://t.co/y5GYCCgg3b

— Cell Reports Medicine (@CellRepMed) May 3, 2023

RCT | Investigational 4-Antigen Staphylococcus aureus vaccine fails to prevent infections in spinal surgery

12 May, 2023 | 13:12h | UTC

Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STRIVE Randomized Clinical Trial – Clinical Infectious Diseases

Commentary on Twitter

Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STRIVE Randomized Clinical Trial

✅ Just Accepted
🔓 Open Access
🔗 https://t.co/eFVufc7rzi pic.twitter.com/XdylTWa66v

— Clinical Infectious Diseases (@CIDJournal) May 3, 2023

RCT | High-dose statin loading prior to CABG shows no benefit in major cardiac and cerebrovascular events

11 May, 2023 | 12:10h | UTC

Statin loading before coronary artery bypass grafting: a randomized trial – European Heart Journal (link to abstract – $ for full-text)

Commentary: Statin Loading No Help Before Bypass Surgery: StaRT-CABG – TCTMD

Commentary on Twitter

Statin loading before coronary artery bypass grafting: a randomised trial https://t.co/br15X5lf7k @escardio #EHJ #ESCYoung @rladeiraslopes @ehj_ed pic.twitter.com/aQFlsJfaed

— European Society of Cardiology Journals (@ESC_Journals) May 8, 2023

RCT | Effect of repeated low-level red light on myopia prevention among children in China with premyopia

10 May, 2023 | 15:52h | UTC

Effect of Repeated Low-level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial – JAMA Network Open

Commentary: Repeated Low-Level Red-Light Intervention Prevents Myopia in Children – HealthDay

Interventions for myopia control in children: a living systematic review and network meta‐analysis – Cochrane Library

RCT | Effect of low-concentration atropine eyedrops vs. placebo on myopia incidence in children

Crossover RCT | Spectacle lenses with highly aspherical lenslets for slowing myopia.

RCT | Effect of text messaging parents of school-aged children on outdoor time to control myopia.

RCT | Myopia control effect of repeated low-level red-light therapy in children.

RCT: Spectacle lenses with aspherical lenslets for myopia control vs. single-vision spectacle lenses.

Randomized trial: Effect of High add power, medium add power, or single-vision contact lenses on myopia progression in children

Commentary on Twitter

RCT: Repeated low-level red-light (RLRL) is a novel and effective intervention for myopia prevention in children with premyopia, up to 54% reduction in incident myopia within 12 months, with good user acceptability and safety. https://t.co/geMajH5ms8

— JAMA Network Open (@JAMANetworkOpen) April 26, 2023

RCT | Safety of integrated MDA of azithromycin, albendazole and ivermectin vs. standard treatment regimens

10 May, 2023 | 15:24h | UTC

Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia – eClinicalMedicine

RCT | Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor–positive breast cancer

9 May, 2023 | 14:32h | UTC

Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

RCT | Tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced esophageal squamous cell carcinoma

8 May, 2023 | 13:04h | UTC

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

NOW OF: Interim analysis of the RATIONALE-306 trial of 1st-line tislelizumab + chemo vs placebo + chemo in adv or metastatic oesophageal squamous cell carcinoma—median OS 17·2 mo (95% CI 15·8–20·1) vs 10·6 mo (9·3–12·1; HR 0·66, 95% CI 0·54–0·80; p<0·0001)https://t.co/25lyg2Ef0o pic.twitter.com/vizCPVd8bj

— The Lancet Oncology (@TheLancetOncol) April 18, 2023

RCT | Long-term survival benefit with abiraterone plus ADT in metastatic PC, but no advantage with enzalutamide association

8 May, 2023 | 13:02h | UTC

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol – The Lancet Oncology

Commentary on Twitter

NEW: Final results from two randomised ph 3 trials of the STAMPEDE platform protocol suggest that enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. #pcsm https://t.co/P1uqzE4Wsv pic.twitter.com/l8U7DQZIoe

— The Lancet Oncology (@TheLancetOncol) May 4, 2023

RCT | Ibrutinib plus rituximab improve CLL PFS vs chemoimmunotherapy, but increased unexplained/cardiac deaths

8 May, 2023 | 13:00h | UTC

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology

RCT | Bacterial decolonization for prevention of radiation dermatitis

8 May, 2023 | 12:46h | UTC

Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)

News Release: A Simple Antibacterial Treatment Solves a Severe Skin Problem Caused by Radiation Therapy – Montefiore Einstein Cancer Center

Commentary on Twitter

Rand trial of 75 pts w/breast cancer + 2 with head/neck cancer showed no pts treated w/bacterial decolonization (BD) developed >gr 1 acute rad'n dermatitis (ARD), vs 24% of pts treated with standard of care, suggesting BD may be preventive vs ARD. https://t.co/6FAFH9kMt1 #RadOnc

— JAMA Oncology (@JAMAOnc) May 4, 2023

RCT | Prednisone fails to enhance live birth outcomes in women with recurrent implantation failure

5 May, 2023 | 15:31h | UTC

Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization: A Randomized Clinical Trial – JAMA (free for a limited period)

See also: Visual Abstract

RCT | Adding Bevacizumab to trifluridine–tipiracil enhances overall survival in refractory metastatic colorectal cancer

5 May, 2023 | 15:13h | UTC

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

Among patients with metastatic colorectal cancer, treatment with trifluridine–tipiracil plus bevacizumab as third-line therapy resulted in longer overall survival than trifluridine–tipiracil alone (SUNLIGHT trial). https://t.co/C4DZvyiZiD pic.twitter.com/gHTR9jbJS5

— NEJM (@NEJM) May 3, 2023

RCT | Best endovascular treatment first strategy yields better outcomes for chronic limb ischemia vs. vein bypass first strategy

3 May, 2023 | 15:39h | UTC

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial – The Lancet

Commentary: BASIL-2 Supports Endo-First Strategy for CLTI With Infrapopliteal Disease – TCTMD

Cluster RCT | Eat, sleep, console approach vs. usual care for neonatal opioid withdrawal

3 May, 2023 | 15:35h | UTC

Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: “Eat, Sleep, Console” reduces hospital stay and need for medication among opioid-exposed infants – NIH News Releases

Commentary on Twitter

In this randomized trial, infants who were treated with the Eat, Sleep, Console model for neonatal opioid withdrawal syndrome had a significantly shorter hospital stay than those in the usual-care group. Full results of the ESC-NOW trial: https://t.co/13j7a5DhZd #PAS2023 pic.twitter.com/so5jqIVwpi

— NEJM (@NEJM) April 30, 2023

RCT | Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis

3 May, 2023 | 15:04h | UTC

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial – JAMA Dermatology

Commentary: Tralokinumab Efficacious, Well-Tolerated for Adolescents with Atopic Dermatitis – HCP Live

Commentary on Twitter

The ECZTRA 6 trial showed that targeted IL-13 inhibition with tralokinumab was efficacious and well tolerated in adolescents with moderate-to-severe AD, suggesting that it is a valuable treatment option in this age group. https://t.co/h36BW4XThE

— JAMA Dermatology (@JAMADerm) April 19, 2023

RCT | Effect of multimodal prehabilitation in improving outcomes following colorectal cancer surgery

3 May, 2023 | 14:52h | UTC

Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery: The PREHAB Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)

Commentary: Prehabilitation Prior to CRC Surgery Reduces Postoperative Complications – Cancer Therapy Advisor

Commentary on Twitter

Patients undergoing resection for nonmetastasized colorectal cancer may benefit from a 4-week multimodal prehabilitation program. https://t.co/e3TO1IdBPJ

— JAMA Surgery (@JAMASurgery) March 29, 2023

RCT | Recurrence outcomes following laparoscopic elective sigmoid resection vs. conservative treatment following diverticulitis

3 May, 2023 | 14:54h | UTC

Quality-of-Life and Recurrence Outcomes Following Laparoscopic Elective Sigmoid Resection vs Conservative Treatment Following Diverticulitis: Prespecified 2-Year Analysis of the LASER Randomized Clinical Trial – JAMA Surgery

Author Interview: Outcomes Following Laparoscopic Elective Sigmoid Resection vs Conservative Treatment Following Diverticulitis – JAMA

Commentary on Twitter

In this study, elective sigmoid resection improved quality of life and decreased recurrence of diverticulitis in 2-year follow-up; these findings may help in decision-making regarding when to proceed to elective surgery for diverticulitis. https://t.co/fKkkQMu7T2

— JAMA Surgery (@JAMASurgery) April 19, 2023

RCT | Hypotension-avoidance and hypertension-avoidance strategies resulted in similar outcomes in noncardiac surgery

2 May, 2023 | 13:54h | UTC

Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery: An International Randomized Controlled Trial – Annals of Internal Medicine (link to abstract – $ for full-text)

News Release: Hypotensive-avoidance strategies not associated with decrease in postoperative hypotension or adverse outcomes – American College of Physicians

Commentary: Hypotension-Avoidance No Better than Hypertension-Avoidance for Reducing Post-Op Adverse Events – HCP Live

Commentary on Twitter

Finally published-POISE-3 showed no diff in effects on major vasc complic between 2 alternative BP mgmt strategies. Probably easiest to continue current regimen.
Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery https://t.co/GIR4jAL07H

— Steven Cohn, MD (@preopconsult) April 24, 2023

RCT | Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer

2 May, 2023 | 13:36h | UTC

Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial – JAMA Surgery (free for a limited period)

Invited Commentary: Heated Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer–Restarting the Fire – JAMA Surgery (free for a limited period)

Commentary on Twitter

Hyperthermic intraperitoneal chemotherapy with mitomycin C along with complete cytoreduction improved locoregional control in patients with locally advanced colorectal cancer and should be considered for treatment of locally advanced colorectal cancer. https://t.co/hOM4TvgILB

— JAMA Surgery (@JAMASurgery) April 26, 2023

RCT | Lung volume reduction surgery vs. endobronchial valves in patients with emphysema

2 May, 2023 | 13:29h | UTC

Lung volume reduction surgery versus endobronchial valves: a randomised controlled trial – European Respiratory Journal

Commentary on Twitter

ERJ: In this first randomised study to compare lung volume reduction surgery and endobronchial valve placement in people who are suitable for both treatments, surgery did not produce substantially superior outcomes at 1 year post-procedure https://t.co/cFIVZijSJg pic.twitter.com/ZqRCgxYwLS

— ERS publications (@ERSpublications) May 1, 2023